**ALU 301-10 Endnotes**

 “NCI Budget and Appropriations”. *Cancer.gov.* National Cancer Institute, 4 Apr. 2015. Web. 4 Jan. 2016.

 Howlader, Nadia, H. M. Noone, M., et al. SEER Cancer Statistics Review, 1975-2012. *seer.cancer.gov.* National Cancer Institute. Apr. 2015. Web. 10 Sep. 2015.

 Takaya, K. L., T. Yoshimasa, H. Arai, N. Tamura, Y. Miyamoto, H. Itoh, K. Nakao. “Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin.” [*J Mol Med (Berl)*.](http://www.ncbi.nlm.nih.gov/pubmed/8912182) 74.10 (1996): 617-21.

 Nagy, Rebecca, Kevin Sweet and Charles Eng. “Highly penetrant hereditary cancer syndromes.” *Oncogene.*23.38 (2004): 6445-6470.

 Landrigan, Phillip J., William Nicholson, Yasunsuke Suzuki and Joseph Ladou. “The Hazards of Chrysotile Asbestos: A Critical Review.” *Industrial Health.* 37 (1999): 271-280.

 Sittum M., M. Buljan, S.O. Bulic and D. Simic. “The mechanisms of UV radiation in the development of malignant melanoma.” *Collegium Antrpologicum.* 31 .Supplement 1 (2007): 13-16.

 “Human papillomavirus (HPV) and cervical cancer.” *who.int/mediacentre/factsheets.* World Health Organization. Mar. 2015. Web. 4 Jan. 2016.

 Geng, Linguyun and Xin Wang. “Epstein-Barr Virus-associated lymphoproliferative disorders; experimental and clinical developments.” *International Journal of Clinical Experimental Medicine.* 8.9 (2015): 14656-14671.

 Adachi, Keishi and Kiji Tamada. “Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.” *Cancer Science.* 106(2015): 945-950.

 Hiddermann, Wolfgang, et al. “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood.* 106(2005): 3725-3732.

 Hartman, JT, M. Haap, H. G. Kopp and H.P. Lipp. “Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects”. *Current Drug Metabolism*. 10.5 (2009): 470-481.

 Sasaki, K., et al. “Relative survival in patients with chronic-phase chronic myeloid leukemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials”. *Lancet Haematology.*2.5 (2015): 186-93.

 Sandler, Alan, et al. “Paclitaxel-Carboplatin Alone of with Bevacizumab for Non-Small-Cell Lung Cancer”. *New England Journal of Medicine.* 355 (2006): 2542-50.

 Kurran, Kevin J., Hollie J. Pegram and Renier J. Brentjens. “Chimeric Antigen Receptors for T cell Immunotherapy: Current Understanding and Future Direction”. *Journal of Genetic Medicine.* 14.6 (2012): 405-415.

 “SEER Stat Fact Sheets: Lung and Bronchus Cancer.” *Seer.cancer.gov/statfacts/html/lungb.html.* National Cancer Institute Surveillance, Epidemiology and End Results Program. Apr. 2018. Web. 7 Jan. 2019.

 “Lung Cancer Risks”. *Lungcancer.org.* lungcancer.org A Program of CancerCARE. Jan. 2016. Web. 7 Jan. 2016.

 U.S. Department of Health and Human Services. “The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General.”Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.

 “Health Risk of Radon”. *Epa.gov.* EPA- United States Environmental Protection Agency. Jan. 2016. Web. 7 Jan. 2016.

 “Lung Cancer Risk Factors”. *Cancerresearchuk.org.* Cancer Research UK. 8 Nov. 2013. Web. 7 Jan. 2016.

 American Lung Association. “Trends in Lung Cancer Morbidity and Mortality”. American Lung Association Epidemiology and Statistics Unit. Nov. 2014.

 Ibid. 15

 Berg, Christine, et. al. “Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening.” *New England Journal of Medicine.* 365.5 (2011): 395-409.

 Ibid. 15

 Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). “SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics”. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.

 National Comprehensive Cancer Network. “NCCN Clinical Practice Guidelines in Oncology - Non-Small Cell Lung Cancer” version 1.2016. 10/23/15.

 American Cancer Society. “Cancer Facts & Figures 2019.” American Cancer Society. 2019.

 “SEER Stat Fact Sheets: Pancreas Cancer.” *Seer.cancer.gov/statfacts/html/pancreas.html.* National Cancer Institute Surveillance, Epidemiology and End Results Program. Apr. 2015. Web. 7 Jan. 2016.

 Ibid.

 Ibid Ries

 Tanaka, Masao, et al. “International consensus guidelines 2012 for the management of IPMN and MCH of the pancreas”. *Pancreatology.* 12 (2012): 186-197.

 Edge, Stephen B. (editor). “AJCC Cancer Staging Manual”, seventh edition. American Joint Committee on Cancer. 2010.

 Ibid. Ries. Extra space below

 Ibid. ACS

 El-Seray, Hashem B. and Jessica A. Davila. “Surveillance for hepatocellular carcinoma: in whom and how?” *Therapeutic Advances in Gastroenterology.* 4.1(2011): 5-10.

 Ribero, D., S.A. Curley, H. Imamura, et al. “Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection.” *Annals of Surgical Oncology.* 15(2008): 986-992.

 National Comprehensive Cancer Network. “NCCN Clinical Practice Guidelines in Oncology – Hepatobiliary Cancers” version 2.2015. 2/6/15.

 “SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct Cancer.” *Seer.cancer.gov/statfacts/html/livibd.html.* National Cancer Institute Surveillance, Epidemiology and End Results Program. Apr. 2015. Web. 10 Jan. 2016.

 Ibid. (Edge).

 Ibid. (NCCN).

 Ibid. ACS

 Hashibe, Mia, Paul Brennan, Shu-chun Chuang, et al. “Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium.” *Cancer Epidemiology Biomarkers and Prevention.* 182.2(2009): 541-550.

 Brown, L.M., D.P. Check and S.S. Devesa.” Oral cavity and pharynx cancer incidence trends by subsite in the United States: changing gender patterns.” *Journal of Oncology*. 2012(2012):6494-98.

 Vokes, Everett E., Nishant Agrawal and Tanguy Y. Seiwert. “HPV-Associated Head and Neck Cancer”. *JNCI: Journal of the National Cancer Institute.* 107.12(2015): 1-7.

 National Comprehensive Cancer Network. “NCCN Clinical Practice Guidelines in Oncology – Head and Neck Cancers” version 1.2015. 5/12/15.

 Ibid. Ries

 Ibid. ACS

 Ibid. Ries

 Ibid. AJCC

 National Comprehensive Cancer Network. “NCCN Clinical Practice Guidelines in Oncology – Thyroid Carcinoma” version 2.2015. 7/29/15.

 Ibid. Ries

 Moyer, VA. “Screening for Prostate Cancer: US Preventive Services Task Force recommendation statement.” *Annals of Internal Medicine*. 157.2(2012): 120-134.

 Fakih, Marwan G. and Aruna Padmanabhan. “CEA Monitoring in Colorectal Cancer.” *Oncology (Williston Park).* 20.6 (2006): 579-587.

 Mikkleson, Barbara. “CA-125”. *Snopes.com/medical/disease/ca125.asp.* 11 Mar. 2009. Web. 14 Jan. 2016.

 Tang, Taylor. “Questions and Answers about the CA-125 Test.” *Johns Hopkins Pathology, Ovarian Cancer.* 8 Aug. 2003. Web. 14 Jan. 2016.

 Ibid. Edge

 Boeck, S. P. Stieber, S. Holdenrieder, et al. “Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer.” *Oncology* 70.4(2006). 255-264.

 National Cancer Institute. “Tumor Markers”. *Cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet.* 4 Nov. 2015. Web. 14 Jan. 2016.

 National Cancer Institute. “Fast Stats”. *Seer.cancer.gov/faststats.* National Institutes of Health. Web. 16 Jan. 2016.